Milbank Advises CVC Capital Partners on the Sale of a Majority Stake in Hellenic Healthcare Group to PureHealth

Milbank LLP advised CVC Capital Partners Fund VI (CVC) on the disposal of its majority stake in the Hellenic Healthcare Group (HHG) to PureHealth Holding PJSC (PureHealth) in a transaction that values HHG at EUR 2.2 billion.

PureHealth, the largest healthcare group in the Middle East, has agreed to acquire a 60% stake in HHG, the largest private healthcare provider in Greece and Cyprus. HHG is currently owned 90% by CVC and 10% by Mr Dimitris Spyridis, HHG CEO. PureHealth will acquire a 60% stake in HHG, with CVC retaining 35% ownership, while CEO Dimitris Spyridis will retain a 5% stake in the company. Following completion of the transaction (currently subject to regulatory approvals), CVC and HHG Management will retain a 40% stake in HHG, continuing as strategic partners to support the Company’s growth and transformation.

CVC is a leading global private markets manager with approximately €191 billion of assets under management.

“We are delighted to have supported CVC with this significant European disposal which required complex structuring and close collaboration with the CVC team”, said corporate partner Lisa O’Neill.

The Milbank deal team advising CVC was led by partners Lisa O’Neill (Global Corporate/M&A, London), Apostolos Gkoutzinis (Corporate Finance and Securities, London) and Lara Watt (Global Corporate/M&A, London) and associates Robbie Hay and Drew MacDonald (both Global Corporate/M&A, London).

The team also included partners Alan Rafferty (Tax, London) and Tom Canning (Litigation, London) associates Lewis Whiteoak (Global Corporate/M&A, London), Jade Du Berry (Tax, London), and Michael Bingham (Litigation, London) and trainee Abdulla Abdulla-Zada (Global Corporate/M&A, London).